101581-13-9

Basic information

• Product Name: 2-Chloro-5-Methoxy-4-nitro-benzoic acid
• Synonyms: 2-Chloro-5-Methoxy-4-nitro-benzoic acid
• CAS NO: 101581-13-9
• Molecular Formula: C₈H₆ClNO₅
• Molecular Weight: 231.58994
• Mol File: 101581-13-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Chloro-5-Methoxy-4-nitro-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-Methoxy-4-nitro-benzoic acid(101581-13-9)
• EPA Substance Registry System: 2-Chloro-5-Methoxy-4-nitro-benzoic acid(101581-13-9)

Safety Data

• Hazardous Substances Data: 101581-13-9(Hazardous Substances Data)

Upstream product

• 56961-30-9 2-chloro-5-hydroxybenzoic acid 
• 7147-89-9 4-chloro-5-methyl-2-nitrophenol 
• 101080-03-9 1-chloro-4-methoxy-2-methyl-5-nitro-benzene 
• 186581-53-3 diazomethane 
• 98555-62-5 2-chloro-5-hydroxy-4-nitro-benzoic acid 

Downstream Products

• 1001347-19-8 4-amino-2-chloro-5-methoxybenzoic acid 
• 1401423-33-3 (2-chloro-5-methoxy-4-nitrophenyl)(morpholino)methanone 
• 1351761-80-2 [2-chloro-5-methoxy-4-(4-methylamino-5-trifluoromethylpyrimidin-2-ylamino)phenyl]morpholin-4-ylmethanone 
• 1362692-44-1 (4-amino-2-chloro-5-methoxyphenyl)(morpholino)-methanone 
• 1356016-30-2 4-amino-2-chloro-5-methoxy-N-phenylbenzamide 
• 1356016-29-9 2-chloro-5-methoxy-4-nitro-N-phenyl-benzamide 
• 1349744-88-2 methyl 2-chloro-5-methoxy-4-nitrobenzoate 
• 1360616-09-6 (2-chloro-5-methoxy-4-nitro-phenyl)-methanol 

Relevant articles and documents

NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (1): or a salt, N-oxide or tautomer thereof; wherein R1 is cyano or C1-4 alkyl; R2 is hydrogen or C1-4 alkyl; R3 is hydrogen or C1-4 alkyl; R4 and R5 are the same or different and each is selected from hydrogen, saturated C1-4 hydrocarbyl and saturated C1-4 hydrocarbyloxy; R6 and R7 are the same or different and each is selected from hydrogen, halogen, CN, C1-4 alkyl and C1-4 alkoxy wherein the C1-4 alkyl and C1-4 alkoxy are each optionally substituted with hydroxy, C1-2 alkoxy or by one or more flourine atoms; R8 is hydrogen or C1-4 alkyl; Q is an alkylene chain of 1 to 4 carbon atoms in length between the moiety Ar and the nitrogen atom N, wherein one or more of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with one or two C1-4 alkyl groups, or wherein one carbon atom of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with a group -CH2CH2- which together with the said one carbon atom forms a cyclopropyl group; m is 1, 2, 3 or 4; n is 0 or 1; and Ar is a monocyclic or bicyclic aryl or heteroaryl group of 5 to 10 ring members containing 0, 1, 2, 3 or 4 heteroatom ring members selected from O, N and S, the aryl or heteroaryl group being optionally substituted with one to four substituents R13 as defined in the claims. The compounds are inhibitors of Chk-1 kinase and are active against cancers.